Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODERN: MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
NCT05987241Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2024
- Primary completion
- Sep 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of nivolumab and relatlimab in urothelial carcinoma (UC) (4 cohorts), sponsored by National Cancer Institute. Primary endpoints: Proportion of patients who are circulating tumor DNA negative at 12 weeks, Overall Survival at 5 years and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05987241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987241.